<DOC>
	<DOCNO>NCT01485874</DOCNO>
	<brief_summary>The purpose trial determine whether BIBF 1120 safely combine pegylated liposomal doxorubicin ( phase I ) , determine clinical activity combination patient platinum-resistant ovarian cancer ( phase II ) .</brief_summary>
	<brief_title>Doxorubicin + BIBF 1120 Patients Ovarian Cancer</brief_title>
	<detailed_description>OUTLINE : This phase I/II multi-center study . Phase I : All patient receive fix dose pegylated liposomal doxorubicin ( Doxil ) 40 mg/m2 administer IV every 28 day . The dose BIBF 1120 escalate successive cohort patient . A maximum 12 cycle combine therapy administer correspond maximum cumulative dose PLD 480 mg/m2 . Continuation therapy single agent BIBF 1120 may continue select patient . The escalation phase follow standard 3+3 design . Patients accrue dose level cohort 3-6 evaluable patient . Escalation continue DLT observe , high dose level reach , medical judgment indicate . An expansion cohort 3 6 patient treat MTD ( high dose level MTD reach ) , order ensure tolerability regimen prior initiate Phase II component study . Phase II : Patients receive fix dose pegylated liposomal doxorubicin ( Doxil ) 40 mg/m2 administer IV every 28 day . Patients treat either dose Level +2 MTD dose level BIBF 1120 define Phase I cohort . Each cycle 28 day . Patients continue treatment combination therapy total 12 cycle . ECOG Performance Status 0-1 Life Expectancy : Not specify Hematopoietic : - Absolute neutrophil count ≥ 1500 cells/mm3 - White cell blood count ≥ 3000 cells/mm3 - Hemoglobin ≥ 9.0 g/dL ( post-transfusion ) - Platelets ≥ 100,000/mm3 ( post-transfusion ) Hepatic : - Aspartate aminotransferase alanine aminotransferase less equal 2.5 time upper limit normal ( ULN ) - Total serum bilirubin ≤ 1.5 time ULN - Alkaline phosphatase ≤ 2.5 time ULN Renal : - Creatinine level ≤ 1.5 time ULN Cardiovascular : - Baseline leave ventricular ejection fraction great 50 % - International Normalized ratio ( INR ) ≤ 1.5 time ULN , except patient stable dos coumadin low molecular weight heparin NOTE : Patients stable dos coumadin low molecular weight heparin eligible anticoagulant dos stable bleeding complication record . - Partial thromboplastin time ( PTT ) ≤1.5 time ULN This study terminate due drug availability Phase II never open .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Platinumresistant ( recurrence within 6 month platinumcontaining regimen ) platinum refractory ( progression platinum ) disease . Measurable disease define RECIST v1.1 criterion screen test Be ≥18 year age time provide write informed consent participation . Give write , informed consent participation protocol . Must consent correlative blood sample collection . Be least 4 week last treatment allow recovery prior toxicity Grade 1 le . The following exception allow : hormonal therapy 1 week washout ; radiation therapy 3 week washout ; weekly chemotherapy 3 week washout Patients come experimental therapy biological agent long half life ( e.g. , antibody ) expect cause myelotoxicity treatment least 4 week . Negative serum pregnancy test within 14 day prior study entry practice effective form contraception hysterectomy and/or oophorectomy part prior treatment Prior therapy pegylated liposomal doxorubicin doxorubicin . Prior therapy BIBF 1120 . Prior antiangiogenic therapy tyrosine kinase inhibitor ( e.g . sorafenib , sunitinib , others ) . Note : Prior therapy bevacizumab allow , provide least 3 month elapse since last dose bevacizumab . Grade 2 great neuropathy , time registration . Active cancer within last 5 year , exception superficial skin cancer ( basal cell squamous cell skin carcinoma ) , carcinoma situ cervix , Stage I endometrial cancer le 50 % invasion myometrium , adequately treated Stage I II cancer complete remission . Presence active infection require antibiotic treatment , time registration . Presence uncontrolled serious medical condition psychiatric illness determine treat physician , time registration . Known history immune deficiency receive combination antiretroviral therapy Known clinically manifest brain metastasis , progressive neurologic dysfunction may develop , would confound evaluation neurologic adverse event . Presence gastrointestinal disorder abnormality would influence absorption study drug . Presence uncontrolled hypertension , arrhythmia , congestive heart failure angina , time registration . Patients myocardial infarction cardiac surgery least 6 month event free active symptom . Serious illness concomitant nononcological disease neurologic , psychiatric , infection disease laboratory abnormality may increase risk associate study participation study drug administration . Major injury within past 4 week prior start study treatment incomplete wound heal and/or plan surgery ontreatment study period . History clinically significant hemorrhagic thromboembolic event past 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BIBF 1120</keyword>
</DOC>